Your browser doesn't support javascript.
loading
Association study of human leukocyte antigen variants and idiopathic pulmonary fibrosis.
Guillen-Guio, Beatriz; Paynton, Megan L; Allen, Richard J; Chin, Daniel P W; Donoghue, Lauren J; Stockwell, Amy; Leavy, Olivia C; Hernandez-Beeftink, Tamara; Reynolds, Carl; Cullinan, Paul; Martinez, Fernando; Booth, Helen L; Fahy, William A; Hall, Ian P; Hart, Simon P; Hill, Mike R; Hirani, Nik; Hubbard, Richard B; McAnulty, Robin J; Millar, Ann B; Navaratnam, Vidya; Oballa, Eunice; Parfrey, Helen; Saini, Gauri; Sayers, Ian; Tobin, Martin D; Whyte, Moira K B; Adegunsoye, Ayodeji; Kaminski, Naftali; Ma, Shwu-Fan; Strek, Mary E; Zhang, Yingze; Fingerlin, Tasha E; Molina-Molina, Maria; Neighbors, Margaret; Sheng, X Rebecca; Oldham, Justin M; Maher, Toby M; Molyneaux, Philip L; Flores, Carlos; Noth, Imre; Schwartz, David A; Yaspan, Brian L; Jenkins, R Gisli; Wain, Louise V; Hollox, Edward J.
Afiliação
  • Guillen-Guio B; Department of Population Health Sciences, University of Leicester, Leicester, UK.
  • Paynton ML; NIHR Leicester Biomedical Research Centre, Leicester, UK.
  • Allen RJ; Joint first authors.
  • Chin DPW; Department of Population Health Sciences, University of Leicester, Leicester, UK.
  • Donoghue LJ; Joint first authors.
  • Stockwell A; Department of Population Health Sciences, University of Leicester, Leicester, UK.
  • Leavy OC; NIHR Leicester Biomedical Research Centre, Leicester, UK.
  • Hernandez-Beeftink T; Department of Population Health Sciences, University of Leicester, Leicester, UK.
  • Reynolds C; NIHR Leicester Biomedical Research Centre, Leicester, UK.
  • Cullinan P; Genentech, San Francisco, CA, USA.
  • Martinez F; Genentech, San Francisco, CA, USA.
  • Booth HL; Department of Population Health Sciences, University of Leicester, Leicester, UK.
  • Fahy WA; NIHR Leicester Biomedical Research Centre, Leicester, UK.
  • Hall IP; Department of Population Health Sciences, University of Leicester, Leicester, UK.
  • Hart SP; NIHR Leicester Biomedical Research Centre, Leicester, UK.
  • Hill MR; National Heart & Lung Institute, Imperial College London, London, UK.
  • Hirani N; National Heart & Lung Institute, Imperial College London, London, UK.
  • Hubbard RB; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
  • McAnulty RJ; University College Hospital, University College London, London, UK.
  • Millar AB; GlaxoSmithKline, London, UK.
  • Navaratnam V; School of Medicine, University of Nottingham, Nottingham, UK.
  • Oballa E; National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham, UK.
  • Parfrey H; Hull York Medical School, University of Hull, Hull, UK.
  • Saini G; MRC Population Health Unit, University of Oxford, Oxford, UK.
  • Sayers I; Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
  • Tobin MD; School of Medicine, University of Nottingham, Nottingham, UK.
  • Whyte MKB; National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham, UK.
  • Adegunsoye A; Division of Medicine, University College London, London, UK.
  • Kaminski N; Bristol Medical School, University of Bristol, Bristol, UK.
  • Ma SF; Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK.
  • Strek ME; National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Zhang Y; Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Fingerlin TE; GlaxoSmithKline, London, UK.
  • Molina-Molina M; Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
  • Neighbors M; School of Medicine, University of Nottingham, Nottingham, UK.
  • Sheng XR; Centre for Respiratory Research, NIHR Nottingham Biomedical Research Centre, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
  • Oldham JM; Department of Population Health Sciences, University of Leicester, Leicester, UK.
  • Maher TM; NIHR Leicester Biomedical Research Centre, Leicester, UK.
  • Molyneaux PL; Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
  • Flores C; Department of Medicine, University of Chicago, Chicago, IL, USA.
  • Noth I; Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Schwartz DA; Department of Medicine, University of Virginia, Charlottesville, VA, USA.
  • Yaspan BL; Department of Medicine, University of Chicago, Chicago, IL, USA.
  • Jenkins RG; Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Wain LV; Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO, USA.
  • Hollox EJ; Servei de Pneumologia, Laboratori de Pneumologia Experimental, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain.
ERJ Open Res ; 10(1)2024 Jan.
Article em En | MEDLINE | ID: mdl-38375425
ABSTRACT

Introduction:

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial pneumonia marked by progressive lung fibrosis and a poor prognosis. Recent studies have highlighted the potential role of infection in the pathogenesis of IPF, and a prior association of the HLA-DQB1 gene with idiopathic fibrotic interstitial pneumonia (including IPF) has been reported. Owing to the important role that the human leukocyte antigen (HLA) region plays in the immune response, here we evaluated if HLA genetic variation was associated specifically with IPF risk.

Methods:

We performed a meta-analysis of associations of the HLA region with IPF risk in individuals of European ancestry from seven independent case-control studies of IPF (comprising 5159 cases and 27 459 controls, including a prior study of fibrotic interstitial pneumonia). Single nucleotide polymorphisms, classical HLA alleles and amino acids were analysed and signals meeting a region-wide association threshold of p<4.5×10-4 and a posterior probability of replication >90% were considered significant. We sought to replicate the previously reported HLA-DQB1 association in the subset of studies independent of the original report.

Results:

The meta-analysis of all seven studies identified four significant independent single nucleotide polymorphisms associated with IPF risk. However, none met the posterior probability for replication criterion. The HLA-DQB1 association was not replicated in the independent IPF studies.

Conclusion:

Variation in the HLA region was not consistently associated with risk in studies of IPF. However, this does not preclude the possibility that other genomic regions linked to the immune response may be involved in the aetiology of IPF.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article